These findings imply that liver-derived cancer cells require NFAT5 upregulation to cope with hyperosmotic stress effectively, whereas kidney-derived cancer cells inherently possess the capacity to withstand such conditions without necessitating additional activation of NFAT5. This evidence concerns the gene NFAT5 and cancer.